MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

AI Briefing

• – MapLight Therapeutics completes enrollment in Phase 2 ZEPHYR trial for schizophrenia and Phase 2 IRIS trial for autism spectrum disorder, with topline results expected by mid-August 2026.
• – The company is a clinical-stage biopharmaceutical firm focused on CNS disorders.
• – ML-007C-MA and ML-004 are being evaluated for their therapeutic effectiveness.